Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Lung Diseases
and you are
over 18
years old
The phase for this study is not defined.
Show me locations

The purpose

The study is an interventional, multicentre, prospective, randomized, controlled, single-blind, comparative trial of two processes for adjusting the inhibitor of calcineurin (CNI) dosage in lung transplant recipients. Recipients will be stratified by transplant center and according to the underlying lung disease (affected with cystic fibrosis or not) and will be randomized to either evaluation of calcineurin activity (CN-a) in combination with CNI blood levels versus CNI blood levels alone in a 1:1 ratio. The objective is to compare the proportion of acute rejection that has required a specific curative treatment at 6 months after transplantation between patients in the two groups.

Provided treatments

  • Biological: levels of CNI in whole blood
  • Biological: Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02897895. The sponsor of the trial is Assistance Publique Hopitaux de marseille and it is looking for 134 volunteers for the current phase.
Official trial title: